We are #hiring! Join our team of dedicated professionals at the #IASLC. Current openings include Adm...Read More
Catch up on recent announcements in ILCN, including a @WinshipAtEmory preceptorship for oncologists ...Read More
The IASLC strongly recommends that Europe’s Beating Cancer Plan include #LDCT in revised screening...Read More
The COAST trial studied new immunotherapy combinations in a subset of patients with unresectable loc...Read More
The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational planning process to ensure independence, balance, objectivity and scientific rigor for all Continuing Medical Education (CME) activities.
In compliance with the ACCME Standards, each individual in a position to control the content of a CME activity is required to disclose all financial relationships with ACCME defined ineligible companies. All disclosures are reviewed to identify relevant financial relationships and any conflicts of interest are mitigated before the individual can assume their role in the activity.
Accreditation and Credit Statements
The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity has been approved for AMA PRA Category 1 Credit™.
For the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022), presenter disclosure information will be available for viewing as of September 22, 2022. Presenters are also required to include a disclosure slide listing all relevant financial relationships with commercial interests. CME related questions should be directed to IASLC at [email protected].